Dendritic cells (DCs) are responsible for the induction of immune responses to pathogens, tumors and vaccines as well as for the maintenance of self-tolerance. 1 DCs were first described in the mouse spleen and elegant studies in murine models have demonstrated that these cells are heterogeneous and functionally specialized.
Dendritic cells (DCs) are responsible for the induction of immune responses to pathogens, tumors and vaccines as well as for the maintenance of self-tolerance. 1 DCs were first described in the mouse spleen and elegant studies in murine models have demonstrated that these cells are heterogeneous and functionally specialized. 1 In mice, splenic and lymphoid tissue (LT) DCs were the historical center of research interest but recent work has focused on their migratory counterparts in non-lymphoid tissues (NLTs) such as the skin, gut and lung. 2 the in vivo counterpart of human monocyte-derived DCs are still unclear. The accessibility of the human skin enabled investigations on cutaneous DCs, containing two subsets, which are defined by the expression of CD1c/CD1a and CD14 in the dermis, in addition to epidermal Langerhans cells (LCs). 6 However, the relationships between human blood CD1c + DCs and CD141 + DCs with skin CD1c/CD1a + DCs and CD14 + DCs are uncertain. CD1c+ and CLEC9A+ DCs have been demonstrated in human lymph nodes (LNs). 7 The phenotypic differences, nomenclature issues and 80 million years of independent evolution between mouse and human have prevented an easy translation of results from mouse DC experimentation into knowledge applicable to humans. Dalod and colleagues were the first to attempt steady-state inter-species correlation of DC subsets and suggested by transcriptomic analysis a homologous relationship between human blood CD141 + DCs and CD1c + DCs with mouse splenic CD8 + DCs and CD11b + DCs, respectively. 8 Recently, functional equivalence between human blood and splenic CD141 + DCs with mouse splenic CD8 + DCs was demonstrated. 5 However, the identity of the human tissue crosspresenting DCs, which by virtue of its location constitutes an ideal target for DC-based anticancer therapy, remained elusive. We have recently identified human tissue cross-presenting DCs and aligned the human and mouse NLT-DC networks (Fig. 1) . 9 We developed a 12-parameter flow cytometry strategy to visualize known DC and monocyte subsets in the human blood. By applying the same analysis to cell suspension derived from the human skin, lung and liver we identified a new DC subset, CD141 + DCs, in addition to the known CD1c + DCs and CD14 + DCs, which were distinct from resident macrophages. In the skin, CD141 expression was promiscuous and was detectable on all DC subsets including CD14 + DCs, as recently described. 10 Tissue CD141 + DCs also expressed CD1c and CD1a and hence will be referred to hereafter as CD141 hi DCs, to distinguish them from blood CD141 + DCs and other DC subsets coexpressing CD141. 10 Blood CD141 + DCs are rare (< 0.1% of CD45 + cells) but tissue CD141
hi DCs seem at least 10-fold more abundant. Similar to their circulating counterparts, skin CD141
hi DCs express XCR1, TLR3, CLEC9A and CADM1 Dendritic cells (DCs) are a heterogeneous group of functionally specialized antigen-presenting cells. we recently characterized the human tissue cross-presenting DCs and aligned the human and mouse DC subsets. Our findings will facilitate the translation of murine DC studies to the human setting and aid the design of DC-based vaccine strategies for infection and cancer immunotherapy.
immune functions are often highly conserved across species. Using transcriptomic analysis, we revealed a conserved human cross-presenting CD141 + DC lineage functionally homologous to murine CD8 + LT-DCs and CD103 + NLT-DCs. Interestingly, human CD1c + DC lineage turned out to be homologous to splenic CD4 + DCs but we did not observe a positive association with mouse CD11b + NLT-DCs. In contrast, human CD14 + DCs were closely related to human and mouse monocytes and also surprisingly with mouse lung CD11b + DCs. This suggests that murine tissue CD11b + DCs are heterogeneous and contain a CD14 + monocyte-like cell equivalent.
Cross-presenting DCs are important for cytotoxic anticancer immune responses. Their presence in the human tissue can be exploited for anticancer DC-based vaccine strategies.
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We assessed cross-presentation functions using an in vitro assay, comparing the ability of purified blood and skin DC subsets to cross-present soluble hepatitis B surface (HBs) antigen to an HLA-A*0201 HBs 183-91 -restricted CD8 + T cell clone. CD141
hi DCs were more potent at cross-presentation than all other skin DC subsets including LCs. Cross-presentation by CD141
hi DCs was observed even in the absence of any stimuli but was enhanced in the presence of a cocktail containing lipopolysaccharide (LPS), polyinosinicpolycytidylic acid (polyI:C), interferon (IFN)γ, IFNα TNFα, and interleukin-1β (IL-1β). Similar to skin CD141 hi DCs, blood CD141 + DCs were superior to CD1c + DCs and CD14 + monocytes at cross-presentation.
Correlating mouse and human DC subsets is important to justify the continued use of mice as a model for human immunity.
Furthermore, important (NECL2) transcripts and secrete CXCL10 and tumor necrosis factor α (TNFα). In addition, skin CD141 hi DCs were found migrating spontaneously in response to XCL1, the ligand for the chemokine receptor XCR1.
We observed that blood CD141 + DCs express the skin homing marker CLA but not the lymph node homing marker CCR7, in contrast to tissue CD141 hi DCs which were CLA − but CCR7 + . To test if CD141
hi DCs migrate to draining LNs, we compared the DC populations in skindraining LNs with tonsil, which lacks afferent lymphatics. DCs migrating from the periphery were only present in skindraining LNs and could be identified by comparatively higher expression levels of HLA-DR and lower expression levels of CD11c. CD141
hi tissue DCs migrating in the LNs retained the expression of CD1c and CD1a and were distinguishable from resident CD141 + LN DCs, which were CD1c − and CD1a − . Co-stimulatory and DC activation markers, including CD80, CD83 and CD86, were expressed 
